Cognition Therapeutics (CGTX) Income from Continuing Operations (2020 - 2026)
Cognition Therapeutics (CGTX) reported Income from Continuing Operations of 8822000.0 for Q1 2026, up 35.98% year-over-year from 6487734.02 in Q1 2025, and up 35.49% on a QoQ basis from 13676000.0 in Q4 2025.
Cognition Therapeutics (CGTX) has 7 years of Income from Continuing Operations data on file, last reported at 8822000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 35.98% year-over-year to 8822000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42854000.0 (up 20.14% YoY) and the FY2025 annual result came in at 47812000.0, down 40.74% from the prior year.
- Income from Continuing Operations grew to 8822000.0 in Q1 2026 per CGTX's latest filing, from 13676000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3838000.0 in Q1 2022 and bottomed at 15198000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 12625000.0 (2022), against an average of 10763705.88.
- The widest annual swing landed in 2022, when Income from Continuing Operations tumbled 1821.08%; it then soared 55.93% in 2025.
- Tracing CGTX's Income from Continuing Operations over 5 years: stood at 9300000.0 in 2022, then tumbled by 63.42% to 15198000.0 in 2023, then gained by 29.41% to 10728000.0 in 2024, then retreated by 27.48% to 13676000.0 in 2025, then surged by 35.49% to 8822000.0 in 2026.
- Per Business Quant, the three latest CGTX Income from Continuing Operations figures stand at 8822000.0 (Q1 2026), 13676000.0 (Q4 2025), and 6375000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Cognition Therapeutics | 648,270.00 | 648,270.00 | - | -8.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.82 Mn |
| Dec 31, 2025 | -13.68 Mn |
| Sep 30, 2025 | -6.38 Mn |
| Jun 30, 2025 | -13.98 Mn |
| Mar 31, 2025 | -13.78 Mn |
| Dec 31, 2024 | -10.73 Mn |
| Sep 30, 2024 | -14.47 Mn |
| Jun 30, 2024 | -14.69 Mn |
| Mar 31, 2024 | -14.11 Mn |
| Dec 31, 2023 | -15.20 Mn |
| Sep 30, 2023 | -14.75 Mn |
| Jun 30, 2023 | -4.73 Mn |
| Mar 31, 2023 | -6.17 Mn |
| Dec 31, 2022 | -9.30 Mn |
| Sep 30, 2022 | -12.63 Mn |
| Jun 30, 2022 | -5.75 Mn |
| Mar 31, 2022 | -3.84 Mn |
| Dec 31, 2021 | -11.81 Mn |
| Sep 30, 2021 | -5.22 Mn |
| Jun 30, 2021 | -1.49 Mn |
| Mar 31, 2021 | 223,000.00 |
| Dec 31, 2020 | -4.12 Mn |
| Sep 30, 2020 | -4.46 Mn |